IFNG and neoplasm: In another pre-clinical study using a genital tract TC-1 tumor model, Bialkowski et al. demonstrated that the combination of E7-TriMix mRNA vaccine (2.5 μg of each TriMix component and 5 μg of E7 antigen, administered on day 8 and 13) with cisplatin (4 mg/kg, administered on days 8, 9, 15, and 16) caused an increase in E7-specific T cells within tumors, and secretion of IFNγ, compared to the spleen.